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Abstract
Background: Uterine fibroids are the most common benign tumor in women. Among those with fibroids, approximately 30%
become symptomatic, with abnormal uterine bleeding, pelvic pain, and bulk symptoms. Despite the high prevalence of fibroids,
little information is available regarding symptoms, treatment choices, and outcomes for patients.
Objective: A Canada-wide patient registry was established to understand the real-world practice. This registry included patient
presentation and treatment preferences, health care provider attitudes, and clinical outcomes in the management of symptomatic
uterine fibroids.
Methods: This study is a prospective, noninterventional, observational patient registry. It will include women diagnosed with
uterine fibroids and being managed for symptoms. Participant inclusion criteria were (1) at least 18 years of age, (2) premenopausal
with a confirmed diagnosis of uterine fibroids, and associated symptoms, and (3) initiating treatment (drug intervention, procedure
intervention, or a combination of both) or watchful waiting. Patients (or legal representative) must understand the nature of the
project and provide written informed consent before enrollment. Participant exclusion criteria were (1) they have known or
suspected clinically significant pelvic pathology not associated with uterine fibroids, and (2) they are undergoing an emergency
hysterectomy at the initial visit. Outcomes will be evaluated in the context of routine clinical practice.
Results: Participant recruitment of this registry began in July 2015. This study currently has a total sample of 1500 patients.
Conclusions: This registry, a first in Canada, will accumulate evidence on the risks and benefits of watchful waiting, and medical
and procedural interventions. It will contribute to enhancing access to treatment options for patients.
Trial Registration: ClinicalTrials.gov NCT02580578; https://clinicaltrials.gov/ct2/show/NCT02580578 (Archived by WebCite
at http://www.webcitation.org/6yax4Hpvr)
International Registered Report Identifier (IRRID): RR1-10.2196/10926
(JMIR Res Protoc 2018;7(11):e10926) doi: 10.2196/10926
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Introduction
Uterine
fibroids
(UF)
are
benign,
monoclonal,
hormone-sensitive, smooth muscle tumors that represent the
most common solid pelvic tumor in women [1-3]. They affect
20% to 40% of women during their reproductive years [4].
Despite their prevalence, very little is known about the etiology
of the disease, burden of illness, and quality of life associated
with the condition. Although most patients with UF are
asymptomatic, UF can cause heavy and prolonged menstrual
bleeding, pelvic pressure or pain, bulk symptoms, and
reproductive dysfunction. Patients with UF show increased use
of analgesics, sanitary products, and health care resources. There
are more physician visits, increased absenteeism, and a decline
in energy, and overall activities, including sexual activity [5].
Apart from epidemiologic data, the natural history of UF is
poorly understood.
In addition to the palpation of an enlarged irregular uterine
contour on pelvic examination, ultrasonography is used to
confirm the diagnosis of UF [6]. Recently magnetic resonance
imaging (MRI) has gained popularity, but the cost and access
to this technology prohibit routine screening. In a uterus with
fewer than 5 lesions, ultrasonography appears to be equally
effective as detection by MRI and virtually identical for
assessing their size and location [7]. However, when the number
of lesions is higher, MRI exceeds the technical limitations of
ultrasound in precise fibroid mapping and characterization.
A significant issue in the field of fibroid identification is the
necessity for differentiating fibroids from other pathologies
such as adenomyomas and uterine neoplasms. Although
uncommon in women less than 40 years old [8], these conditions
require the differential diagnosis with fibroids because the
treatment options and prognosis may differ [9]. Patterns of use
and accuracy of diagnostic imaging of UF have not been studied
systematically in the publicly funded Canadian health care
system.
Treatment options for UF patients should ideally address 3
goals: (1) relief of signs and symptoms, (2) sustained reduction
in fibroid size, and (3) retention or enhancement of fertility if
desired. At the same time, treatment should also aim to improve
quality of life, minimize side effects, be convenient for patients,
and target UF directly [10]. Medical, procedural, or combined
treatment options are available for patients with symptomatic
UF. However, there were no medications to treat these women
in Canada until 2013 when ulipristal acetate (UPA) was
approved.
UPA has shown to be more effective than placebo [11] and as
effective as the injectable gonadotropin-releasing hormone
agonist leuprolide acetate [12] for treating UF symptoms.
Leuprolide acetate received Health Canada indication for
preoperative improvement of anemia in symptomatic UF women
in 2017 [13]. The uptake, long-term clinical and patient-reported
outcomes, efficacy, safety, as well as the pharmacoeconomics
of indicated and off-label treatment options for these patients
in Canada, have yet to be determined.
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In the past 15 years, there has been only 1 completed registry
for patients with UF who have undergone uterine artery
embolization [14]. In the United States, the COMPARE-UF
trial is underway [15]. A Canadian prospective patient registry
provides the opportunity to address many unanswered questions,
particularly the management patterns and outcomes associated
with different treatments for UF and patients’ preferences for,
and satisfaction with, managing UF symptoms.
With this background in mind, the objectives of this study are
to (1) enhance the understanding of the natural history of
symptomatic UF, (2) understand Canadian provider and patient
preferences for managing symptomatic UF, (3) examine factors
that have an impact on the uptake of UF treatment options and
compliance with therapy, (4) examine the effectiveness and
efficiency of UF treatment options across ethnicities in
real-world practice in Canada, and (5) provide real-world data
characterizing long-term clinical and patient-reported outcomes,
including effectiveness and safety, associated with different UF
management options.

Methods
Overall Study Design and Plan
The CAnadian women wiTh Uterine fibroids REgistry
(CAPTURE) is a prospective, observational cohort study
(NCT02580578) that will include women who have been
diagnosed with symptomatic UF. Outcomes will be evaluated
as part of routine clinical practice. The target study population
will include patients with a diagnosis of UF from 20 study sites
across Canada. Participating physicians will not be required to
perform any medical procedure that is outside their normal
clinical practice. Serious and nonserious adverse drug reactions
(ADRs) will be followed up as per local standard of care and
as expected in an observational research study. Similarly, both
serious and nonserious adverse events (AEs) during and
following procedural intervention will be reported. Each study
site was responsible for local ethics review board approval as
per their institutional policy.

Participants
Approximately 1000 patients will be enrolled from 20 Canadian
investigational sites, including both academic and community
practices. Inclusion criteria for the study are premenopausal
women at least 18 years of age with confirmed diagnosis and
symptoms associated with UF that are being observed (watchful
waiting), currently being treated, or initiating treatment (drug
intervention, procedure intervention, or a combination of both).
All patients (and the patient’s authorized legal representative)
should understand the nature of the project and provide written
informed consent before or at the initial study visit. Exclusion
criteria for the study are known or suspected significant pelvic
pathology not associated with UF and patients undergoing an
emergency hysterectomy at the initial visit.

Withdrawal of Participants
Participation in this registry is voluntary, and patients may
withdraw at any time and for any reason. Once the patient
informs the site staff that she wishes to withdraw her
participation, a “Withdrawal from registry” form will be
JMIR Res Protoc 2018 | vol. 7 | iss. 11 | e10926 | p. 2
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completed with the date and reason. The patient will be informed
that all data collected up to that point will be used in the
analysis. From that point on, the patient will no longer be
contacted for the registry, and no further data on that participant
will be collected.

Participants Lost to Follow Up
Efforts will be made to keep patients in the registry for at least
24 months. A patient will be considered to have missed a study
visit after all efforts have been made by site personnel to contact
the patient to reschedule within 1 month of the missed
appointment. If a patient has missed a follow-up visit, all efforts
should be made to reach the patient to ensure that subsequent
follow-up visits are completed.

Study Visits
The visit schedule is comprised of 4 study visits (baseline, 3to 6-month, 12-month, and 24-month; Table 1) and pre-, intra-,
and postoperative visits for patients undergoing procedural
interventions (Table 2).

Baseline Visit
The baseline visit will involve (1) obtaining informed consent,
(2) checking for inclusion/exclusion criteria, (3) collecting

demographic information, (4) obtaining a medical history, and
(5) assessing patient current health status. This will be followed
by patient assessments that involve questions on UFs using the
EuroQol 5-Dimensions 5-Levels (EQ-5D-5L) survey, the
Uterine Fibroid Symptom and Quality of Life (UFS-QOL)
questionnaire, the Aberdeen Menorrhagia Severity Scale
(AMSS) questionnaire, and evaluation for concomitant
medications and history of previous procedural interventions.
The EQ-5D-5L [16] is a validated 5-question survey with a
visual analog scale used to measure health outcomes that
provides a simple descriptive profile and a single index value
for health status. The UFS-QOL [17] is a validated 37-question
disease-specific symptom and health-related quality of life
questionnaire for UF. It has been used extensively in studies to
assess the impact of the disease in patients and treatment options
in randomized clinical trials. The AMSS questionnaire is a
validated 15-question survey that evaluates the severity and
effect of bleeding that occurs during and between menses. There
are 7 baseline questions for UF patients asking about the purpose
of their visit and what outcome they are hoping to achieve.
If deemed eligible for registry participation, the patient will
return for a visit in 3 to 6 months. When available, imaging and
other test results (biopsies, blood work) will also be documented.

Table 1. Schedule of events of the CAPTURE study at baseline and scheduled visits.
Examinations

Baseline

3- to 6-montha

12-montha

24-montha

Signed informed consent formb

✓

—

—

—

Inclusion/exclusion criteria

✓

—

—

—

Demographics

✓

—

—

—

Medical history

✓

—

—

—

Fertility wishes

✓

✓

✓

✓

Blood work (hemoglobin)c

✓

✓

✓

✓

Gynecologic symptoms

✓

✓

✓

✓

Ultrasound of fibroids

✓

✓

✓

✓

Type and location of fibroids

✓

—

—

—

Endometrial biopsyc

✓

—

—

—

Planned/updated management plan

✓

✓

✓

✓

d

✓

✓

✓

✓

Bleeding assessmente

✓

✓

✓

✓

EQ-5D-5Lf

✓

✓

✓

✓

Concomitant medications

✓

✓

✓

✓

Adverse events

—

✓

✓

✓

UFS-QOL

a

Scheduled follow-up visits

Visits can be performed by telephone or in clinic; however, an in-person visit is preferred.

b

Must be obtained from patient prior to study enrollment.

c

To be captured if available.

d

UFS-QOL: Uterine Fibroid Symptom and Quality of Life questionnaire.

e

Tool for assessment is the Aberdeen Menorrhagia Severity Scale questionnaire.

f

EQ-5D-5L: EuroQol 5-dimensions 5-levels survey used to measure health status.
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Table 2. Schedule of events of the CAPTURE study at procedural intervention and hysterectomy.
Examinations

Procedural interventiona

Hysterectomy

Preoperative

Intraoperative

Postoperative

1-year follow up

Signed informed consent form

—

—

—

—

Inclusion/exclusion criteria

—

—

—

—

Demographics

—

—

—

—

Medical history

—

—

—

—

Fertility wishes

—

—

—

—

Blood work (hemoglobin)b

✓

—

—

—

Gynecologic symptoms

—

—

—

✓

Ultrasound of fibroids

✓

—

—

—

Type and location of fibroids

—

—

—

—

Endometrial biopsy

—

—

✓

—

Planned/updated management plan

✓

—

—

—

UFS-QOLc

✓

—

✓

✓

Bleeding assessmentd

✓

—

✓

—

e

✓

—

✓

✓

Concomitant medications

✓

—

—

—

Adverse event

✓

✓

✓

—

EQ-5D-5L

a

Procedural intervention is not mandatory in the registry, and data will be collected if physician and patient decide on a procedural intervention to
address symptoms associated with uterine fibroids.
b

To be captured if available.

c

UFS-QOL: Uterine Fibroid Symptom and Quality of Life questionnaire.

d

Not required if patient undergoes hysterectomy procedure. Otherwise the tool for assessment is the Aberdeen Menorrhagia Severity Scale questionnaire.

e

EQ-5D-5L: EuroQol 5-dimensions 5-levels survey used to measure health status.

Visits at Three to Six Months, Twelve Months, and
Twenty-Four Months
These visits can be performed in the clinic or via telephone;
however, an in-person visit is preferred. Participants will be
evaluated for updates and an assessment of the management
plan, and for ADRs (if medication was prescribed at the previous
visit). Also, patient questionnaires (EQ-5D-5L, UFS-QOL, and
AMSS) will be administered. Follow up will occur after the
baseline meeting at 3 to 6 months, 12 months, and 24 months.

Preoperative Visit

morcellation (if performed), will be documented. In the case of
myomectomy, fibroid cleavage planes and density (subjective)
of the fibroids will be obtained as well.

Postoperative Visit
This visit will only occur if the patient and physician agree on
a procedural intervention. During this visit, information on AEs
following the procedure, pathology, and patient questionnaires
(EQ-5D-5L, UFS-QOL, and AMSS) will be recorded.

Hysterectomy Postoperative Follow Up

This visit will only occur if the patient and physician agree on
a procedural intervention. During this visit, participants will be
evaluated for updates and an assessment of the management
plan, and for ADRs (if medication was prescribed at the previous
visit). Also, patient questionnaires (EQ-5D-5L, UFS-QOL, and
AMSS) will be administered.

If a patient undergoes a hysterectomy, a follow-up visit will
occur 1 year after the hysterectomy (in addition to the
postoperative visit). This follow up will replace all remaining
scheduled follow-up study visits. Information on postoperative
symptoms, overall satisfaction, UFS-QOL-Hysterectomy, and
EQ-5D-5L will be obtained. Once this follow up is completed,
the patient will be deemed to have completed all study visits.

Intraoperative Visit

Unscheduled Visits

This visit will only occur if the patient and physician agree on
a procedural intervention. During this visit, information on the
procedure performed and the AEs will be obtained. Specific
details on the type of procedure, route, and surgical times will
be recorded. Intraoperative description of outcomes, including

Unscheduled visits (other than the prescribed appointments)
are any unexpected visits, including emergency assessments or
changes to care plans. Participants will be assessed for the reason
of the visit, update and evaluation of the management plan, and
ADRs (if medication was previously prescribed).

http://www.researchprotocols.org/2018/11/e10926/

XSL• FO
RenderX

JMIR Res Protoc 2018 | vol. 7 | iss. 11 | e10926 | p. 4
(page number not for citation purposes)

JMIR RESEARCH PROTOCOLS

Pregnancy Follow Up
If an unplanned pregnancy occurs with hormonal medical
therapy during this study, a serious AE will be recorded. Also,
the “Pregnancy follow up” form will be completed to capture
baseline pregnancy information. If the patient consents to be
followed up on the outcome of the pregnancy, then postdelivery
follow-up information will be collected once available. No study
visits will be completed during the pregnancy. Following
delivery, the patient will resume the study visit schedule until
completion.

Assessment of Clinical Efficacy and Safety
This is a patient registry that tracks the routine practice and
management of patients with UF in Canada. The physician will
collect data at the initial and follow-up visits between 3 to 6
months, 12 months, and 24 months. Also, if a procedural
intervention is performed, pre-, intra-, and postoperative data
will be captured. Patients will be asked to complete the
EQ-5D-5L, UFS-QOL, and the brief bleeding questionnaires
as per the visit schedule outlined in Tables 1 and 2.

Duration of Study
The duration of the study will be 2 years from the recruitment
of the final patient, which occurred in February 2018. It is
expected that the last visit of the final patient will occur in
February 2020.

Statistical Methods
The analysis will include all patients enrolled in the study who
have been entered into the database.

Statistical Analysis
The goal of this study is to establish a registry of Canadian
patients with symptomatic UF. We have recruited a sample of
1500 patients to help describe the management of UF in this
population.
Initially, exploratory data analysis will summarize all variables
of interest by reporting means and standard deviations for
continuous variables, and frequencies (percentages) for
categorical variables. Analysis of variance will be used to
compare continuous variables between treatment groups of
interest. Chi-square tests will be used to compare categorical
variables between the 2 groups. A linear mixed model will be
employed to examine the association between treatment groups
while adjusting for other covariates of clinical interest. These
variables include demographics, UF history, comorbidities,
medications, and medical tests (both current and previous).
The model will include a time-by-treatment-interaction term to
determine whether treatments have improved quality of life
relative to other treatment groups. Furthermore, a random effect
will be included at the patient level to incorporate correlation
arising from the repeated measures design of the study.
Since this is an observational registry, missing data and
drop-outs (ie, early study termination) are expected. Statistical
techniques will be used to examine the missing data (including
logistic regression) and, if feasible, multiple imputations will
be used to make any adjustments.
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Additionally, where imputation techniques are not adequate,
sensitivity analysis will be employed. All parameter estimates,
confidence intervals, and P values will be reported from the
model, and a 2-sided significance level of .05 will be used.
The original terms used by participating physicians to identify
ADRs will be coded using the Medical Dictionary for
Regulatory Activities (MedDRA). The MedDRA system organ
class and preferred term will be used to present the number and
percentage of patients with ADRs, the drug relationship,
seriousness, and intensity of ADRs. Chi-square tests will be
employed to compare the number of ADRs between groups of
interest.

Data Management Process
Overall coordination of the registry will be led by a steering
committee that includes 6 academic gynecologists and 1
community gynecologist. Committee responsibilities include
establishing the registry database and protocol, appointing a
scientific committee for data analysis and interpretation, and
governing the dissemination of the registry findings through a
publication plan. All members of the steering committee have
a vote on decision making, with the Chair providing a deciding
vote in the event of a tie. The study sponsor, Allergan Canada,
does not have a vote or seat on the steering committee but will
facilitate meetings.
All study data will be captured on HealthDiary, which is a
Web-based electronic data-capture system. Data will be
managed by the Applied Health Research Center (AHRC), a
service unit within the HUB Health Research Solutions and
fully integrated with the Li Ka Shing Knowledge Institute of
St. Michael’s Hospital, Toronto, Ontario, Canada. The AHRC
is a full-service clinical research coordinating center staffed
with highly trained individuals including statisticians,
methodologists, research coordinators, contract and finance
managers, and research informatics specialists. The facility will
serve as the data management center. It has managed large
randomized trials, cohort studies, and patient registries across
provincial and international borders, ensuring privacy
regulations using state-of-the-art, Web-based, data management
software. The center will be responsible for developing the
electronic case report form (eCRF), conducting data
management, and issuing and clarifying queries with the
participating sites. The research database includes automated
edit and logic checks to assist with the data management
activities. Data entry screens and edit checks will be tested with
mock patient data and removed from the database before
beginning the study. In addition to programmed edit and logic
checks, manual data verification, and consistency checks will
be performed to ensure valid, relevant, and complete data for
analysis.
Medical history and concomitant medical conditions/diseases
will be coded according to MedDRA. Data handling procedures,
including edit check specifications, data entry guide, authorized
corrections, coding instructions, and locking procedure, will be
detailed in the study data management plan.
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Data Quality Assurance
The database will be secured and enable quality control to be
performed at the time of data entry. Quality control will focus
on value ranges and missing data. Any discrepancies that occur
during eCRF data entry will be flagged in real time by the
system and will be saved until addressed by the data entry
personnel.
In compliance with Good Clinical Practice and regulatory
requirements, the sponsor, a third party on behalf of the sponsor,
health regulatory agencies, or research ethics boards may
conduct quality assurance audits at any time during or following
the study. The participating investigator must agree to allow
auditors direct access to all project-related documents, including
source documents, and must agree to allocate their time and the
time of their project staff to the auditors to discuss findings and
issues.

Results
Participant recruitment for this registry began in July 2015. The
registry has recruited 1500 patients, with the first patient
enrolled in the second half of 2015. Patient follow up will occur
for up to 2 years, with the last patient visit occurring in 2020.
It is anticipated that national/industrial funding will be available
to continue this initiative beyond 2020 based on the information
generated from this registry.

Discussion
Importance of the CAPTURE Registry
Despite the prominence of UF and their detrimental effects on
patient health, little is known about many aspects of the
condition, including the etiology of the disease, the natural
history of UF, the impact of UF on fertility and pregnancy
outcomes, and the effectiveness of UF treatments in real-world
clinical practice. There are virtually no well-designed, long-term,
epidemiologic studies published in this disease area. The
evidence on the comparative long-term effectiveness of
treatment options is also of poor quality. The Agency for
Healthcare Research and Quality (AHRQ) has published reviews
on the state of the evidence for the management of UF in 2001
and 2007. A more recent review was published by Singh and
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Belland [10] outlining clinical data on the medical and surgical
management of UF along with a treatment algorithm to assist
health care professionals.
Our literature search for established UF registries revealed only
1 in the past 15 years called the FIBROID Registry. This was
a multicenter, prospective, longitudinal study of the short- and
long-term outcomes of uterine artery embolization [14]. Despite
the lack of data on the management of UF, the future of
obtaining real-world data in this area appears promising. In
addition to this registry in Canada, registries in both the United
States and Europe have been announced or are currently
underway. In the second half of 2014, the Patient-Centered
Outcomes Research Institute and AHRQ announced that the
Duke University School of Medicine’s Department of Obstetrics
and Gynecology and the Duke Clinical Research Institute will
lead a 5-year patient registry to evaluate the effectiveness of
different treatment strategies for UF patients.
In Canada, there is a lack of documented data characterizing
the UF patient population, treatment options, and outcomes
associated with women who have UF. Also, no data exist
regarding patient preference and satisfaction related to their
management. Moreover, with the introduction of UPA—the
first Health Canada-approved medication for the treatment of
UF—an evaluation of effectiveness and safety is desirable. It
should be noted that UPA is undergoing a clinical investigation
in the United States and is currently not approved. In Europe,
a prospective, observational, noninterventional study is ongoing
to document real-world data related to current treatment patterns
and outcomes associated with UPA in patients with symptoms
associated with UF. This registry is collecting valuable
real-world data in Canada on the medical and procedural
management of UF to address these issues.

Potential Limitations
This registry has some limitations. The instruments used at
different visits are self-reported, which may result in reporting
bias. The noninterventional design can lead to selection bias as
well as confounding. Finally, failure to follow up and the
expected attrition of the participants at subsequent visits
following recruitment could impact on the sample size, thus
limiting the external validity.
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